Metabolism of the vitamin D3 analogue EB1O89 alters receptor complex formation and reduces promoter selectivity

British Journal of Pharmacology

Volumn 125, Issue 4, 1998, Pages 607-614

  Quack, Marcus ^a   Hansen, Christina Mørk ^b   Binderup, Ernst ^b   Kissmeyer, Anne Marie ^b   Carlberg, Carsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEO Pharmaceutical Products   (Denmark)

Author keywords

Limited protease digestion; Receptor mutagenesis; Vitamin D3 analogues; Vitamin D3 receptor

Indexed keywords

COLECALCIFEROL DERIVATIVE; DRUG METABOLITE; SEOCALCITOL; ANTINEOPLASTIC AGENT; CALCITRIOL; CALCITRIOL RECEPTOR; CARCINOGEN; COLECALCIFEROL; DRUG DERIVATIVE; LIGAND;

ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; COMPLEX FORMATION; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; METABOLISM; PROTEIN CONFORMATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; CARCINOGENS; CHOLECALCIFEROL; FEMALE; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, CALCITRIOL; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032174574     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702086     Document Type: Article

References (33)

1. BOURGUET, W., RUFF, M., CHAMBON, P., GRONEMEYER, H. & MORAD, D. (1995). Crystal structure of the ligand binding domain of the human nuclear receptor RXR-α. Nature, 375, 377-382.
2. 3: interplay with retinoid and thyroid hormone signalling. Eur. J. Biochem., 231, 517-527.
3. CARLBERG, C. (1996a). The concept of multiple vitamin D pathways. J. Invest. Dermatol. Symp. Proc., 1, 10-14.
4. 3 receptor in the context of the nuclear receptor superfamily: the central role of retinoid X receptor. Endocrine, 4, 91-105.
5. CARLBERG, C., BENDIK, I., WYSS, A., MEIER, E., STURZENBECKER, L.J., GRIPPO, J.F. & HUNZIKER, W. (1993). Two nuclear signalling pathways for vitamin D. Nature, 361, 657-660.
6. COLSTON, K.W., MACKAY, A.G., JAMES, S.Y., BINDERUP, L., CHANDER, S. & COOMBES, P.C. (1992). EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol., 44, 2273-2280.
7. DANIELIAN, P.S., WHITE, R., LEES, J.A. & PARKER, M.G. (1992). Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J., 11, 1025-1033.
8. 3 analogue is related to promoter selectivity. J. Cell. Biochem., 66, 552-562.
9. DELUCA, H.F., KRISINGER, J. & DARWISH, H. (1990). The vitamin D system. Kidney Int., 38, S2-S8.
10. DURAND, B., SAUNDERS, M., GAUDON, C., ROY, B., LOSSON, R. & CHAMBON, P. (1994). Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoid acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element. EMBO J., 13, 5370-5382.
11. 3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with transcription factor IIB, in vitro. J. Biol. Chem., 272, 14592-14599.
12. 3 receptor binding site found in the rat atrial natriuretic factor promoter. Biochem. Biophys Res. Commun., 218, 882-886.
13. KISSMEYER, A.-M., BINDERUP, E., BINDERUP, L., MØRK HANSEN, C., RASTRUP ANDERSEN, N., MAKIN, H.L.J., SCHROEDER, N.J., SHANKAR, V.N. & JONES, G. (1997). Metabolism of the vitamin D analog EB1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol., 53, 1087-1097.
14. KISSMEYER, A.-M., MATHIASEN, I.S., LATINI, S. & BINDERUP, L. (1995). Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine, 3, 263-266.
15. MANGELSDORF, D.J., THUMMEL, C., BEATO, M., HERRLICH, P., SCHÜTZ, G., UMESONO, K., BLUMBERG, B., KASTNER, P., MARK, M., CHAMBON, P. & EVANS, R.M. (1995). The nuclear receptor superfamily: the second decade. Cell, 83, 835-839.
16. MASUYAMA, H., BROWNFIELD, C.M., ST-ARNAUD, R. & MACDONALD, P.N. (1997). Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol., 11, 1507-1517.
17. MATHIASEN, I.S., COLSTON, K.W. & BINDERUP, L. (1993). EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J. Steroid Biochem. Molec. Biol., 46, 365-371.
18. MØRK HANSEN, C. & MÄENPÄÄ, P.H. (1997). EB1089 - a novel vitamin D analog with strong antiproliferative and differentiation inducing effects on target cells. Biochem. Pharmacol., 54, 1173-1179.
19. MOØRK HANSEN, C., MATHIASEN, I.S. & BINDERUP, L. (1996). The anti-proliferative and differentiation-inducing effects of vitamin D analogues are not determined by the binding affinity for the vitamin D receptor alone. J. Invest. Dermatol. Symp. Proc., 1, 44-48.
20. 3 receptor. Biochem. J., 235, 561-568.
21. 3 analogues is not related to the AP-1 pathway, but related to promoter selectivity. Oncogene, 11, 1853-1858.
22. 3 receptor is functionally linked to the transactivation domain 2 (AF-2). Nucleic Acids Res., 24, 4513-4519.
23. 3 correlates well with gene activation. J. Cell. Biochem., 62, 325-333.
24. 3 receptors: structure and function in transcription. Annu. Rev. Nutr., 11, 189-216.
25. POLS, H.A.P., BIRKENHÄGER, J.C. & VAN LEEUVEN, J.P.T.M. (1994). Vitamin D analogues: from molecule to clinical application. Clin. Endocrinol., 40, 285-291.
26. POTHIER, F., OUELLET, M., JULIEN, J.-P. & GUÉRIN, S.L. (1992). An improved CAT assay for promoter analysis in either transgenic mice or tissue culture cells. DNA Cell Biol., 11, 83-90.
27. RENAUD, J.-P., ROCHEL, N., RUFF, M., VIVAT, V., CHAMBON, P., GRONEMEYER, H. & MORAS, D. (1995). Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature, 378, 681-689.
28. 3 response element identified in the mouse c-fos promoter. Biochem. Biophys. Res. Commun., 230, 646-651.
29. 3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of VDR-RXR heterodimer-mediated transactivation. Mol. Cell. Biol., 15, 1154-1161.
30. SHANKAR, V.N., DILWORTH, F.J., MAKIN, H.L.J., SCHROEDER, N.J., TRAFFORD, D.J.H., KISSMEYER, A.-M., CALVERLEY, M.J., BINDERUP, E. & JONES, G. (1997). Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem. Pharmacol., 53, 783-793.
31. 3 analog KH1060. Proc. Natl. Acad. Sci. U.S.A., 93, 10685-10690.
32. VIETH, R. (1990). The mechanisms of vitamin D toxicity. Bone Mineral., 11, 267-272.
33. WALTERS, M.R. (1992). Newly identified actions of the vitamin D endocrine system. Endocr. Rev., 13, 719-764.